CGTLive®’s Weekly Rewind – December 13, 2024

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Cilta-Cel Boosts MRD Negativity Rates Compared to Standard of Care Therapy in New Multiple Myeloma Data

The results come from patients with lenalidomide-refractory MM treated in the CARTITUDE-4 trial after 1 to 3 lines of prior therapy.

2. Manali Kamdar, MD, on the Curative Potential of Liso-Cel in Third-Line R/R LBCL

The clinical director of lymphoma services at the University of Colorado discussed 5-year follow-up data from the TRANSCEND-NHL-001 clinical trial.

3. Bendamustine Is an Effective Alternative to Fludarabine-Based Lymphodepletion in LBCL

In the wake of fludarabine shortages, lemphodepletion with bendamustine was found to be an effective alternative compared for patients with large B-cell lymphoma being treated with a CD19-directed CAR T-cell therapy.

4. Haydar Frangoul, MD, on Sickle Cell Disease Gene Therapy Exa-Cel's Ability to Prevent VOCs

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed the latest data update from the CLIMB SCD-121 trial evaluating exa-cel.

5. Tabelecleucel Efficacy Sustained in EBV-positive PTLD, as FDA Considers Application

With an FDA deadline pending in January, tabelecleucel remained safe and effective with longer follow-up for Epstein–Barr virus-associated post-transplant lymphoproliferative disease.